34P - Immunotherapy for high-risk neuroblastoma: allogeneic stem cell transplantation and recipient leucocyte infusion

Date 20 November 2015
Event ESMO Symposium on Immuno-Oncology 2015
Session Welcome reception and general Poster viewing
Topics Neuroendocrine Tumours
Presenter Isabelle Dierckx de Casterlé
Citation Annals of Oncology (2015) 26 (suppl_8): 5-14. 10.1093/annonc/mdv514
Authors I. Dierckx de Casterlé, O. Rutgeerts, S. Fevery, C. Lenaerts, M. Waer, A. Billiau, B. Sprangers
  • Immunology And Microbiology - Laboratory Of Experimental Transplantation, KU Leuven, 3000 - Leuven/BE



High-risk neuroblastoma is the most frequent extra-cranial solid tumor in childhood, which is associated with a poor prognosis. To date, no effective or safe therapy is available. Allogeneic stem cell transplantation and recipient leucocyte infusion (RLI) have previously been shown to be effective in murine neuroblastoma models. However, the underlying mechanism of the RLI-induced anti-solid tumor response still needs to be determined. Therefore, we aim at elucidating in detail the effector mechanism of the RLI-induced anti-neuroblastoma effects.


Here, the immunological mechanism of RLI has been investigated using our well-established focal neuroblastoma mouse model.


Post-transplant infusion of recipient leucocytes results in a complete rejection of the donor marrow graft, mediated by RLI-derived alloreactive T cells. Following RLI, recipient-type IFNg- and granzyme B-producing T cells are induced, suggesting that these effector cells are important key players in the observed RLI-mediated anti-neuroblastoma responses.


Our results demonstrate that post-transplant adoptive transfer of recipient-type leucocytes results in significant anti-solid tumor reactivity, mediated by cytotoxic recipient-type T lymphocytes that are induced by the complete rejection of the donor marrow graft.

Clinical trial identification


All authors have declared no conflicts of interest.